je.st
news
Home
› MabVax Therapeutics Receives Orphan Drug Designation For Therapeutic Vaccine To Treat Childhood Cancer Neuroblastoma
MabVax Therapeutics Receives Orphan Drug Designation For Therapeutic Vaccine To Treat Childhood Cancer Neuroblastoma
2014-10-01 14:02:11| drugdiscoveryonline Home Page
MabVax Therapeutics Holdings, Inc. (OTCQB: TELKD), a clinical stage oncology drug development company, announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to the Company's vaccine intended for the treatment of the childhood cancer neuroblastoma
Tags: drug
cancer
treat
receives
Category:Biotechnology and Pharmaceuticals
Latest from this category |
All news |
||||||||||||||||||||
|
|
||||||||||||||||||||